×

FDA panel backs Mannkind's 'Afrezza'

1:42 PM ET Wed, 2 April 2014

Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel to approve his company's inhaled insulin treatment "Afrezza."